Duchenne muscular dystrophy requires a comprehensive treatment approach that combines medical care, physical support, and emerging therapies to help manage symptoms and maintain quality of life for as long as possible.

How Treatment Goals Are Shaped by This Challenging Condition

When a child receives a diagnosis of Duchenne muscular dystrophy, families quickly learn that managing this condition requires a multi-layered approach. The primary goals of treatment focus on slowing the progression of muscle weakness, maintaining mobility and independence for as long as possible, protecting heart and breathing function, and improving overall quality of life. Because this is a progressive condition where muscles gradually lose their ability to function, treatment must adapt as the disease advances through different stages.^[1]

Treatment approaches depend heavily on the stage of disease and the individual characteristics of each patient. What works for a young child who is still walking will differ significantly from what an adolescent in a wheelchair needs, or what a young adult requiring breathing support requires. Medical societies have established care guidelines that recommend a coordinated team approach, bringing together specialists from neurology, cardiology, respiratory medicine, orthopedics, nutrition, and rehabilitation.^[9]

Standard treatments that have been used for years remain the backbone of care, primarily centered on medications called corticosteroids (drugs that reduce inflammation and help preserve muscle strength). At the same time, intensive research efforts continue worldwide, testing new experimental therapies in clinical trials. These investigational treatments aim to address the root genetic cause of Duchenne or target secondary problems that make the disease worse. Families should understand that while there is currently no cure, treatment options continue to expand, offering hope for better outcomes than were possible even a decade ago.^[4]

Standard Approaches to Managing Duchenne Muscular Dystrophy

The foundation of Duchenne treatment has long rested on corticosteroid therapy. These medications work by reducing inflammation in damaged muscles and helping to slow the rate of muscle deterioration. The most commonly prescribed corticosteroids include prednisone, prednisolone, and deflazacort. Studies have shown that when started early and continued long-term, these drugs can help children maintain the ability to walk for months or even years longer than would otherwise be possible.^[9]

Prednisone and prednisolone have been used for decades and represent the oldest, most thoroughly studied corticosteroids in Duchenne care. Deflazacort, marketed under the brand name Emflaza, is a derivative of prednisone that received approval from the U.S. Food and Drug Administration specifically for treating Duchenne in patients aged two years and older. More recently, a newer corticosteroid called vamorolone has also gained approval. These medications are typically started when a child is between the ages of four and six, once diagnosis is confirmed and before significant muscle weakness has developed.^[9]

Treatment with corticosteroids is generally continuous and long-term. Doctors recommend that these medications not be stopped suddenly, as abrupt discontinuation can lead to serious complications, particularly if the body has adapted to the medication over time. The duration of therapy often extends for many years, sometimes throughout the patient’s lifetime, with doses adjusted based on body weight, side effects, and disease progression.^[9]

Beyond corticosteroids, standard treatment includes extensive supportive care. Physical therapy plays a crucial role in maintaining muscle function, preventing contractures (permanent tightening of muscles and tendons that limit joint movement), and supporting mobility. Therapists work with patients on stretching exercises, range-of-motion activities, and strengthening programs tailored to current abilities. As walking becomes more difficult, assistive devices such as braces, walkers, and eventually wheelchairs become necessary.^[1]

Cardiac care represents another essential component of standard treatment. Almost all individuals with Duchenne develop cardiomyopathy (weakening and enlargement of the heart muscle) by their teenage years or earlier. Regular monitoring with electrocardiograms and echocardiograms helps detect heart problems before they cause symptoms. Medications such as ACE inhibitors or beta-blockers are often prescribed to protect heart function and are typically continued lifelong.^[1]

Respiratory management becomes increasingly important as the disease progresses. Breathing muscles weaken over time, making it harder to take deep breaths and clear secretions from the lungs. Patients often need respiratory support devices such as BiPAP machines (devices that help push air into the lungs), cough-assist devices, and eventually mechanical ventilation. Many individuals require assisted ventilation by their twenties, and this support often becomes a permanent part of daily life.^[6]

Nutritional support is also critical, as individuals with Duchenne face unique challenges. Early in the disease, corticosteroid-induced weight gain can be problematic, while later stages may bring difficulties with chewing and swallowing that lead to inadequate nutrition. Dietitians help families plan appropriate meals and may recommend supplements or feeding tubes when necessary.^[9]

Innovative Therapies Being Tested in Clinical Trials

While standard treatments help manage symptoms, they do not address the underlying genetic defect that causes Duchenne. This has driven intensive research into therapies that could restore or replace the missing dystrophin protein (the protein that muscles need to stay strong and intact). Several innovative approaches have emerged from clinical trials, with some already receiving approval and others still under investigation.^[5]

One of the most promising approaches involves exon skipping, a technique that helps cells produce a shortened but partially functional version of dystrophin. The dystrophin gene consists of multiple segments called exons. In many people with Duchenne, mutations disrupt the reading of these exons, leading to no dystrophin production at all. Exon skipping therapies use synthetic molecules called antisense oligonucleotides to essentially trick the cell’s protein-making machinery into skipping over the problematic exon section, allowing production of a truncated but somewhat functional dystrophin protein.^[11]

Several exon skipping drugs have received approval for specific genetic mutations. These medications work only for patients whose particular mutation can be addressed by skipping a specific exon. For example, some drugs target exon 51, others target exon 53, and still others target different exons. Because each drug is mutation-specific, genetic testing is essential to determine which patients might benefit. These therapies are administered by intravenous infusion, typically weekly, and are intended for long-term use. Clinical trials have shown that exon skipping can lead to small increases in dystrophin production in muscle tissue, though the clinical benefits in terms of muscle function have been more modest and variable across patients.^[11]

Gene therapy represents an even more ambitious approach. Instead of trying to skip over problematic gene sections, gene therapy aims to deliver a functional copy of the dystrophin gene directly into muscle cells. Because the full dystrophin gene is too large to fit into current delivery vehicles, researchers have developed a miniaturized version called micro-dystrophin. This smaller gene contains the most critical portions of the full dystrophin gene and can be packaged into viral vectors that serve as delivery vehicles.^[5]

Gene therapy trials have used modified viruses, specifically adeno-associated viruses (AAV), to carry micro-dystrophin genes into muscle cells throughout the body. The therapy is given as a one-time intravenous infusion. Early clinical trial results have shown that gene therapy can lead to micro-dystrophin production in muscles and potentially slow the decline in muscle function. However, these therapies remain in relatively early stages of testing, with ongoing Phase II and Phase III trials evaluating their safety and effectiveness across different age groups and disease stages. Potential challenges include immune responses to the viral vector, variability in how well the gene reaches different muscles, and uncertainty about how long the therapeutic effect will last.^[5]

Another innovative drug that recently gained approval in Europe is givinostat, marketed as Duvyzat. This medication takes a different approach by targeting histone deacetylases (HDAC), proteins that become overactive in dystrophic muscles. Excessive HDAC activity contributes to inflammation and the replacement of muscle tissue with scar tissue and fat. Givinostat works as an HDAC inhibitor, dampening this harmful activity. It is given as an oral suspension taken alongside corticosteroid treatment.^[12]

The approval of givinostat was based on clinical trial data from ambulatory patients (those still able to walk) aged six years and older who were taking corticosteroids. The primary study measured how long it took patients to climb four stairs, a standard test of motor function in Duchenne. Results showed that patients treated with givinostat experienced slower worsening in stair-climbing time compared to those receiving placebo. The difference was statistically significant, though modest: stair-climbing time increased by an average of only 1.25 seconds in the givinostat group compared to 3.03 seconds in the placebo group after 18 months. The most common side effects included diarrhea, abdominal pain, low blood platelet counts, vomiting, elevated blood fats, and fever. Because the initial evidence is still limited, regulatory authorities granted conditional approval with requirements for additional studies to confirm long-term benefits.^[12]

Other therapeutic strategies being explored in clinical trials include approaches to enhance muscle regeneration, reduce inflammation through different pathways, and protect muscle cells from damage. Some trials are testing drugs that aim to increase muscle mass by blocking myostatin (a protein that normally limits muscle growth). Others are investigating compounds that could improve mitochondrial function in muscle cells or reduce oxidative stress. These trials span different phases, from early Phase I safety studies in small numbers of participants to larger Phase III trials comparing experimental treatments directly against standard care.^[11]

Clinical trials for Duchenne are conducted worldwide, including in the United States, Europe, and many other regions. Patient eligibility varies depending on the specific trial but typically includes factors such as age, mutation type, current medication use, disease stage (ambulatory versus non-ambulatory), and baseline muscle function. Some trials specifically recruit younger children, while others focus on adolescents or adults. Families interested in clinical trials should discuss options with their neuromuscular specialist and may need to undergo genetic testing to determine if their child’s specific mutation makes them eligible for mutation-specific therapies.^[13]

Most common treatment methods

• Corticosteroid therapy
  • Prednisone and prednisolone: oldest and most studied corticosteroids used to slow muscle degeneration
  • Deflazacort (Emflaza): approved specifically for Duchenne in patients aged two years and older
  • Vamorolone: newer corticosteroid option with approval for Duchenne treatment
  • Typically started between ages four and six and continued long-term
  • Side effects include weight gain, behavioral changes, growth suppression, bone thinning, cataracts, and increased infection risk
• Physical and rehabilitation therapy
  • Stretching exercises and range-of-motion activities to prevent contractures
  • Use of assistive devices including braces, walkers, and wheelchairs as disease progresses
  • Physical therapy programs tailored to current abilities and disease stage
• Cardiac management
  • Regular monitoring with electrocardiograms and echocardiograms
  • ACE inhibitors and beta-blockers to protect heart function
  • Lifelong cardiac medication to manage cardiomyopathy
• Respiratory support
  • BiPAP machines to assist with breathing
  • Cough-assist devices to help clear lung secretions
  • Mechanical ventilation as breathing muscles weaken
  • Often required by the twenties and may become permanent
• Exon skipping therapies
  • Antisense oligonucleotides that help cells produce partially functional dystrophin
  • Mutation-specific drugs targeting different exons (such as exon 51 or 53)
  • Administered by weekly intravenous infusion
  • Genetic testing required to determine eligibility
• Gene therapy
  • One-time intravenous infusion delivering micro-dystrophin gene using viral vectors
  • Currently in Phase II and Phase III clinical trials
  • Aims to restore dystrophin production throughout body muscles
  • Challenges include immune responses and uncertainty about duration of effect
• HDAC inhibitors
  • Givinostat (Duvyzat): oral suspension approved in Europe for patients aged six and older
  • Reduces inflammation and tissue scarring by inhibiting histone deacetylases
  • Taken alongside corticosteroid treatment
  • Showed modest slowing of motor function decline in clinical trials